KR20010014341A - 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 비사이클릭 벤즈아미드 - Google Patents
위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 비사이클릭 벤즈아미드 Download PDFInfo
- Publication number
- KR20010014341A KR20010014341A KR1019997012492A KR19997012492A KR20010014341A KR 20010014341 A KR20010014341 A KR 20010014341A KR 1019997012492 A KR1019997012492 A KR 1019997012492A KR 19997012492 A KR19997012492 A KR 19997012492A KR 20010014341 A KR20010014341 A KR 20010014341A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- alkyl
- hydrogen
- substituted
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/12—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/16—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
Claims (12)
- 화학식(I)의 화합물, 그의 입체화학적 이성체 형태, 그의 N-옥사이드 형태 또는 그의 약제학적으로 허용되는 산 또는 염기 부가염:상기 식에서,R1및 R2는 함께 화학식-O-CH2-O- (a-1),-O-CH2-CH2- (a-2),-O-CH2-CH2-O- (a-3),-O-CH2-CH2-CH2- (a-4),-O-CH2-CH2-CH2-O- (a-5),-O-CH2-CH2-CH2-CH2- (a-6)의 2가 라디칼을 형성하고,여기에서, 상기 2가 라디칼에서, 하나 또는 두개의 수소 원자가 C1-6알킬로 치환될 수 있으며;R3은 수소 또는 할로이고;R4는 수소 또는 C1-6알킬이며;R5는 수소 또는 C1-6알킬이고;L은 C3-6사이클로알킬, C5-6사이클로알카논, 또는 C2-6알케닐이거나,L은 -Alk-R6(b-1),-Alk-X-R7(b-2)-Alk-Y-C(=O)-R9(b-3) 또는-Alk-Y-C(=O)-NR11R12(b-4)이며,여기에서,각 Alk는 C1-12알칸디일이고;R6는 수소, 하이드록시, 시아노, C1-6알킬술포닐아미노, C3-6사이클로알킬, C5-6사이클로알카논, 또는 Het1이며;R7은 수소, C1-6알킬, 하이드록시C1-6알킬, C3-6사이클로알킬, 또는 Het2이며;X는 O, S, SO2또는 NR8(여기에서, R8은 수소 또는 C1-6알킬이다)이고;R9는 수소, C1-6알킬, C3-6사이클로알킬, C1-6알킬옥시 또는 하이드록시이며;Y는 NR10또는 직접 결합이고(여기에서, R10은 수소 또는 C1-6알킬이다);R11및 R12는 각각 독립적으로 수소, C1-6알킬, C3-6사이클로알킬이거나, R11및 R12는 이들을 갖는 질소원자와 함께 C1-6알킬, 아미노 또는 모노 또는 디(C1-6알킬)아미노에 의해 임의로 치환된, 피롤리디닐 또는 피페리디닐 환을 형성할 수 있거나, R11및 R12는 이들을 갖는 질소원자와 함께 C1-6알킬에 의해 임의로 치환된, 피페라지닐 또는 4-모르폴리닐 라디칼을 형성할 수 있으며,Het1및 Het2는 각각 독립적으로 푸란; C1-6알킬 또는 할로로 치환된 푸란; 테트라하이드로푸란; C1-6알킬로 치환된 테트라하이드로푸란; 디옥솔란; C1-6알킬로 치환된 디옥솔란; 디옥산; C1-6알킬로 치환된 디옥산; 테트라하이드로피란; C1-6알킬로 치환된 테트라하이드로피란; 피롤리디닐; 할로, 하이드록시, 시아노, 또는 C1-6알킬로부터 각각 독립적으로 선택된 하나 또는 두개의 치환체에 의해 치환된 피롤리디닐; 피리디닐; 할로, 하이드록시, 시아노, 또는 C1-6알킬로부터 각각 독립적으로 선택된 하나 또는 두개의 치환체에 의해 치환된 피리디닐; 피리미디닐; 할로, 하이드록시, 시아노, C1-6알킬, C1-6알킬옥시, 아미노 및 모노- 및 디(C1-6알킬)아미노로부터 각각 독립적으로 선택된 하나 또는 두개의 치환체에 의해 치환된 피리미디닐; 피리다지닐; 하이드록시, C1-6알킬옥시, C1-6알킬 또는 할로로부터 각각 독립적으로 선택된 하나 또는 두개의 치환체에 의해 치환된 피리다지닐; 피라지닐; 할로, 하이드록시, 시아노, C1-6알킬, C1-6알킬옥시, 아미노, 모노- 및 디(C1-6알킬)아미노 및 C1-6알킬옥시카보닐로부터 각각 독립적으로 선택된 하나 또는 두개의 치환체에 의해 치환된 피라지닐로부터 선택되거나;Het1은 또한 화학식의 라디칼일 수 있고;Het1및 Het2는 각각 독립적으로 화학식의 라디칼로부터 선택될 수 있으며;R13및 R14는 각각 독립적으로 수소 또는 C1-4알킬이다.
- 제 1 항에 있어서, -OR4라디칼이 트랜스 배위를 갖는 중심 피페리딘 부위의 3-위치에 위치하는 화합물.
- 제 1 항에 있어서, -OR4라디칼이 중심 피페리딘 부위의 4-위치에 위치하는 화합물.
- 제 1 항 내지 제 3 항중 어느 한항에 있어서,L이 C3-6사이클로알킬 또는 C2-6알케닐; 또는 화학식 (b-1)의 라디칼(여기에서, 각 Alk는 C1-6알칸디일이고, R6가 수소, 하이드록시, 시아노, 아미노, C1-6알킬술포닐아미노, C3-6사이클로알킬 또는 Het1(여기에서, Het1는 테트라하이드로푸란; 디옥솔란; C1-6알킬로 치환된 디옥솔란; 테트라하이드로피란; 하이드록시, 할로 및 C1-6알킬로부터 선택된 하나이상의 치환체에 의해 치환된 피리다지닐이다)이다); 또는 화학식(c-1), (c-3) 또는 (c-4)의 라디칼(여기에서, R13은 C1-4알킬이다); 또는 화학식(b-2)의 라디칼(여기에서, Alk는 C1-6알칸디일이고, X가 O 이며, R7이 C1-6알킬 또는 하이드록시C1-6알킬이다); 또는 화학식(b-2)의 라디칼(여기에서, Alk는 C1-6알칸디일이고, R7은 Het2(여기에서, Het2는 C1-6알킬로 치환된 피라지닐이다)이며, X는 NR8(여기에서, R8은 수소 또는 C1-6알킬이다)이다); 또는 화학식(b-3)의 라디칼(여기에서, Y는 직접결합이고, R9는 C1-6알킬, 하이드록시 또는 C1-6알킬옥시이다); 또는 화학식(b-4)의 라디칼(여기에서, Y는 직접결합이고, R11및 R12는 C1-6알킬이거나 이들을 갖는 질소원자와 함께 피롤리디닐을 형성한다)인 화합물.
- 제 4 항에 있어서, L이 부틸; 메톡시, 메틸카보닐 또는 2-메틸-1,3-디옥솔란으로 치환된 프로필, 4-메틸-2-피리다지논 또는 테트라하이드로피라닐로 치환된 에틸; 또는 테트라하이드로푸라닐 또는 테트라하이드로피라닐로 치환된 메틸인 화합물.
- 제 1 항에 있어서, (트랜스)-(-)-4-아미노-5-클로로-2,3-디하이드로-N-[[3-하이드록시-1-(3-메톡시프로필)-4-피페리디닐]메틸]-2,2-디메틸-7-벤조푸란카복스아미드; 그의 약제학적으로 허용되는 산 부가염 또는 N-옥사이드 형태인 화합물.
- 약제학적으로 허용되는 담체 및 치료 활성량의 제 1 항 내지 제 6 항중 어느 한항에 따른 화합물을 함유하는 약제학적 조성물.
- 치료 활성량의 제 1 항 내지 제 6 항중 어느 한항에 따른 화합물을 약제학적으로 허용되는 담체와 밀접히 혼합시키는 제 7 항에 따른 약제학적 조성물을 제조하는 방법.
- 제 1 항 내지 제 6 항중 어느 한항에 있어서, 약제로서 사용하기 위한 화합물.
- 화학식(III)의 화합물, 그의 약제학적으로 허용되는 산 부가염, 또는 그의 입체화학적 이성체 형태:상기 식에서,R1, R2, R3, R4및 R5는 화학식(I)의 화합물에 대해서 제 1 항에서 정의된 바와 같다.
- a) 화학식(II)의 중간체를 반응-불활성 용매중에서, 임의로 적절한 염기의 존재하에서 화학식(III)의 중간체로 N-알킬화시키거나,b) 화학식 L'=O (IV)의 적절한 케톤 또는 알데히드 중간체(여기에서, L'=O는 화학식 L-H(여기에서, C1-12알칸디일 부위의 두개의 제미날 수소는 =O에 의해 치환된다)이다)를 화학식(III)의 중간체와 반응시키거나,c) 화학식(V)의 중간체를 화학식(VI)의 카복실산 유도체 또는 그의 반응성 작용 유도체와 반응시키거나,d) 화학식(VII)의 중간체(여기에서, X는 브로모 또는 요오도이다)를 적절한 촉매 및 3급 아민 존재하의 반응-불활성 용매중에서, 실온 내지 반응 혼합물의 환류온도에서 화학식(V)의 중간체 존재하에 카보닐화시키거나,e) 화학식(I)의 화합물을 공지된 기술의 변환 반응에 따라 서로 전환시키거나; 원한다면, 화학식(I)의 화합물을 약제학적으로 허용되는 산 부가염으로 전환시키거나, 역으로 화학식(I) 화합물의 산 부가염을 알칼리로 유리ㅡ염기 형태로 전환시키거나; 원한다면, 그의 입체화학적 이성체 형태를 제조하여 화학식(I)의 화합물을 제조하는 방법:상기 반응 식에서,라디칼 L, R1, R2, R3, R4및 R5는 제 1 항에서 정의된 바와 같고,W는 적절한 이탈 그룹이다.
- a) 화학식(VIII)의 중간체를 화학식(VI)의 산 또는 그의 적절한 반응성 작용 유도체와 반응 불활성 용매중에서 반응시키고, 이어서 보호 그룹 PG를 탈보호시켜 화학식(III)의 화합물을 수득하거나;b) 화학식(III)의 화합물을 공지기술의 변환 반응에 따라 서로 전환시키거나; 원한다면, 화학식(III)의 화합물을 산부가염으로 전환시키거나, 역으로 화학식(III)의 화합물의 산부가염을 알칼리로 유리 염기 형태로 전환시키거나; 원한다면, 그의 입체화학적 이성체 형태를 제조하여 화학식(III)의 화합물을 제조하는 방법:상기 반응 식에서,PG는 적절한 보호 그룹이고,라디칼 L, R1, R2, R3, R4및 R5는 제 1 항에서 정의된 바와 같으며,W는 적절한 이탈 그룹이다.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97202180.2 | 1997-07-11 | ||
EP97202180 | 1997-07-11 | ||
EP98200624 | 1998-02-27 | ||
EP98200624.9 | 1998-02-27 | ||
PCT/EP1998/004190 WO1999002156A1 (en) | 1997-07-11 | 1998-07-07 | Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivates |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010014341A true KR20010014341A (ko) | 2001-02-26 |
KR100500372B1 KR100500372B1 (ko) | 2005-07-11 |
Family
ID=26146699
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019997012486A KR100885658B1 (ko) | 1997-07-11 | 1998-07-07 | 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 모노사이클릭 벤즈아미드 |
KR10-1999-7012492A KR100500372B1 (ko) | 1997-07-11 | 1998-07-07 | 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 비사이클릭 벤즈아미드 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019997012486A KR100885658B1 (ko) | 1997-07-11 | 1998-07-07 | 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 모노사이클릭 벤즈아미드 |
Country Status (34)
Country | Link |
---|---|
US (10) | US6452013B1 (ko) |
EP (3) | EP0991410B1 (ko) |
JP (2) | JP4530530B2 (ko) |
KR (2) | KR100885658B1 (ko) |
CN (2) | CN1117568C (ko) |
AR (2) | AR013361A1 (ko) |
AT (2) | ATE226820T1 (ko) |
AU (2) | AU747199B2 (ko) |
BG (2) | BG64230B1 (ko) |
BR (2) | BR9811687A (ko) |
CA (2) | CA2295087C (ko) |
CZ (2) | CZ297298B6 (ko) |
DE (2) | DE69820065T2 (ko) |
DK (2) | DK0991410T3 (ko) |
EA (1) | EA002619B1 (ko) |
EE (1) | EE04178B1 (ko) |
ES (2) | ES2187051T3 (ko) |
HK (2) | HK1025093A1 (ko) |
HR (2) | HRP20000005B1 (ko) |
HU (2) | HU227424B1 (ko) |
ID (2) | ID24161A (ko) |
IL (2) | IL133917A (ko) |
MY (2) | MY123199A (ko) |
NO (2) | NO314662B1 (ko) |
NZ (2) | NZ502208A (ko) |
PL (2) | PL190310B1 (ko) |
PT (2) | PT991410E (ko) |
RU (1) | RU2213089C2 (ko) |
SI (2) | SI1000028T1 (ko) |
SK (2) | SK284632B6 (ko) |
TR (2) | TR200000023T2 (ko) |
TW (2) | TW548103B (ko) |
UA (1) | UA67745C2 (ko) |
WO (2) | WO1999002494A1 (ko) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW548103B (en) * | 1997-07-11 | 2003-08-21 | Janssen Pharmaceutica Nv | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
TW570920B (en) * | 1998-12-22 | 2004-01-11 | Janssen Pharmaceutica Nv | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
US20040253179A1 (en) * | 2003-02-26 | 2004-12-16 | Acm Medical Technologies, Inc. | Measuring gastrointestinal parameters |
US20080219928A1 (en) * | 2003-02-26 | 2008-09-11 | Becker Jane A | Measuring Gastrointestinal Parameters |
WO2005003122A1 (en) * | 2003-06-19 | 2005-01-13 | Janssen Pharmaceutica N.V. | 5ht4-antagonistic 4-(aminomethyl)-piperidine benzamides |
ES2336448T3 (es) * | 2003-06-19 | 2010-04-13 | Janssen Pharmaceutica Nv | 4-(aminometil)-piperidina-benzamidas con sustituyentes heterociclicos como antagonistas de 5ht4. |
JO2478B1 (en) * | 2003-06-19 | 2009-01-20 | جانسين فارماسوتيكا ان. في. | (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists |
AU2004251823B2 (en) * | 2003-06-19 | 2010-06-03 | Janssen Pharmaceutica N.V. | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists |
ATE388146T1 (de) | 2004-01-29 | 2008-03-15 | Pfizer | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor |
TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
DE602005016446D1 (de) * | 2004-11-05 | 2009-10-15 | Theravance Inc | 5-HT4-Rezeptoragonistenverbindungen |
ATE431824T1 (de) * | 2004-11-05 | 2009-06-15 | Theravance Inc | Chinolinon-carboxamid-verbindungen |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
PT2522365T (pt) | 2004-11-24 | 2017-02-08 | Meda Pharmaceuticals Inc | Composições que compreendem azelastina e seus métodos de utilização |
ES2347265T3 (es) * | 2004-12-22 | 2010-10-27 | Theravance, Inc. | Compuestos de indazol-carboxamida. |
KR20070107807A (ko) * | 2005-03-02 | 2007-11-07 | 세라밴스 인코포레이티드 | 5-ht4 수용체 아고니스트인 퀴놀리논 화합물 |
TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
GB0603550D0 (en) * | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
US9654833B2 (en) | 2007-06-26 | 2017-05-16 | Broadband Itv, Inc. | Dynamic adjustment of electronic program guide displays based on viewer preferences for minimizing navigation in VOD program selection |
US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
US20110313319A1 (en) * | 2008-11-07 | 2011-12-22 | SAND COUNTY BIOTECHNOLOGY, Inc. | Measuring method for the concentration of intragastric contents |
US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
KR101180174B1 (ko) * | 2010-04-23 | 2012-09-05 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
JP6182989B2 (ja) | 2012-06-28 | 2017-08-23 | セントラル硝子株式会社 | 1,3,3,3−テトラフルオロプロペンの製造方法 |
WO2014083003A1 (en) | 2012-11-27 | 2014-06-05 | Shire International Gmbh | Pro-cognitive compound |
KR101595183B1 (ko) * | 2013-07-25 | 2016-02-17 | 동아에스티 주식회사 | 벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1046052B (it) * | 1973-10-12 | 1980-06-30 | Sigurta Farmaceutici Spa | Processo per la preparazione di i aralchil 4 aminometil piperidin 4 oli |
US4348763A (en) * | 1980-08-07 | 1982-09-07 | Hewlett-Packard Company | Multiple stripe leaky mode laser |
US4711703A (en) | 1982-02-03 | 1987-12-08 | Orbisphere Corporation Wilmington, Succursale De Collonge-Bellerive | Thermal protection method for electroanalytical cell |
DE3416224C2 (de) | 1983-05-06 | 1994-05-05 | Mitsubishi Chem Ind | Verfahren zur Herstellung eines Kohleverflüssigungsöls |
US4772630A (en) | 1984-11-23 | 1988-09-20 | Ciba-Geigy Corp. | Benzamides and their salts |
US4722630A (en) | 1985-09-20 | 1988-02-02 | The Garrett Corporation | Ceramic-metal braze joint |
GB8527052D0 (en) | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
US4910312A (en) | 1985-11-08 | 1990-03-20 | Warner-Lambert Company | Various N-substituted 3-piperidine carboxylic acids or N-substituted 3-pyridinecarboxylic acids and derivatives thereof |
US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
US4746655A (en) * | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
BE1000689A6 (fr) | 1987-07-14 | 1989-03-14 | Donnay Donnay S A Ets | Raquette de tennis, de squash ou sport analogue. |
US5130312A (en) | 1987-07-17 | 1992-07-14 | Janssen Pharmaceutica N.V. | Substituted N-(3-hydroxy-4-piperidinyl)benzamides |
NZ225152A (en) | 1987-07-17 | 1990-04-26 | Janssen Pharmaceutica Nv | Heterocyclically substituted piperidinyl benzamides as pharmaceuticals |
US4906643A (en) | 1987-07-17 | 1990-03-06 | Janssen Pharmaceutica N.V. | Substituted N-(3-hydroxy-4-piperidinyl)benzamides as gastrointestinal agents |
JPH0719937B2 (ja) * | 1987-09-24 | 1995-03-06 | 三井石油化学工業株式会社 | 高周波用積層板およびその製造方法 |
CA1317940C (en) | 1987-09-25 | 1993-05-18 | Georges H. P. Van Daele | Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
US4975439A (en) | 1987-09-25 | 1990-12-04 | Janssen Pharmaceutical N.V. | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
US5041454A (en) | 1987-09-25 | 1991-08-20 | Janssen Pharmaceutica N.V. | Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides |
JP2573017B2 (ja) | 1988-03-08 | 1997-01-16 | 三洋電機株式会社 | ディスクプレーヤ |
US5053412A (en) | 1990-04-10 | 1991-10-01 | Israel Institute For Biological Research | Spiro nitrogen-bridged heterocyclic compounds |
US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
GB9005014D0 (en) | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
US5103141A (en) | 1990-03-08 | 1992-04-07 | U.S. Philips Corporation | Switching arrangement for increasing the white life of a high pressure sodium lamp |
US5534520A (en) | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
US5407938A (en) | 1990-04-10 | 1995-04-18 | Israel Institute For Biological Research | Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines) |
TW213460B (ko) * | 1991-02-15 | 1993-09-21 | Hokuriku Pharmaceutical | |
JPH06510283A (ja) | 1991-08-20 | 1994-11-17 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht4レセプター拮抗薬 |
SG49153A1 (en) | 1991-09-12 | 1998-05-18 | Smithkline Beecham Plc | 5-HT4 receptor antagonists |
IT1252567B (it) * | 1991-12-20 | 1995-06-19 | Italfarmaco Spa | Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi |
WO1993013101A1 (en) * | 1991-12-27 | 1993-07-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound |
AU667874B2 (en) | 1992-02-06 | 1996-04-18 | Smithkline Beecham Plc | Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists |
JPH05236345A (ja) | 1992-02-21 | 1993-09-10 | Nec Ic Microcomput Syst Ltd | 画像用垂直フィルタ回路 |
MX9306311A (es) | 1992-10-13 | 1994-04-29 | Smithkline Beecham Plc | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
US6127379A (en) * | 1993-02-01 | 2000-10-03 | Smithkline Beecham P.L.C. | Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists |
WO1995026953A1 (fr) * | 1994-03-30 | 1995-10-12 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose d'acide benzoïque et son utilisation comme medicament |
US5864039A (en) * | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
TW490465B (en) * | 1994-11-24 | 2002-06-11 | Janssen Pharmaceutica Nv | Enterokinetic benzamide, the preparation process and the pharmaceutical compositions thereof |
GB9507882D0 (en) * | 1995-04-18 | 1995-05-31 | Pharmacia Spa | Substituted dihydrobenzofuran derivatives as 5-ht4 agonists |
EP0873990A1 (en) * | 1995-09-22 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and medicinal use thereof |
US6096761A (en) * | 1996-02-15 | 2000-08-01 | Janssen Pharmaceutica N.V. | Esters of 3-hydroxy-piperidinemethanol derivatives |
KR100469029B1 (ko) * | 1996-02-15 | 2005-05-27 | 얀센 파마슈티카 엔.브이. | 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도 |
TW548103B (en) | 1997-07-11 | 2003-08-21 | Janssen Pharmaceutica Nv | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives |
EP0950243A1 (en) | 1997-10-31 | 1999-10-20 | Deawoo Electronics Co., Ltd. | Cd changer with a driving mechanism operated by a single driving source |
EP1112270B1 (en) * | 1998-09-10 | 2007-03-21 | F. Hoffmann-La Roche Ag | Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists |
-
1998
- 1998-06-12 TW TW087109331A patent/TW548103B/zh not_active IP Right Cessation
- 1998-06-12 TW TW087109332A patent/TW402591B/zh not_active IP Right Cessation
- 1998-07-07 WO PCT/EP1998/004189 patent/WO1999002494A1/en active IP Right Grant
- 1998-07-07 ID IDW2000030A patent/ID24161A/id unknown
- 1998-07-07 PT PT98940158T patent/PT991410E/pt unknown
- 1998-07-07 IL IL13391798A patent/IL133917A/xx not_active IP Right Cessation
- 1998-07-07 UA UA2000010195A patent/UA67745C2/uk unknown
- 1998-07-07 WO PCT/EP1998/004190 patent/WO1999002156A1/en active IP Right Grant
- 1998-07-07 SK SK1734-99A patent/SK284632B6/sk not_active IP Right Cessation
- 1998-07-07 EP EP98940158A patent/EP0991410B1/en not_active Expired - Lifetime
- 1998-07-07 KR KR1019997012486A patent/KR100885658B1/ko not_active IP Right Cessation
- 1998-07-07 RU RU2000103212/04A patent/RU2213089C2/ru active
- 1998-07-07 JP JP2000502022A patent/JP4530530B2/ja not_active Expired - Lifetime
- 1998-07-07 EP EP02075710A patent/EP1206938A1/en not_active Ceased
- 1998-07-07 CN CN98806950A patent/CN1117568C/zh not_active Expired - Lifetime
- 1998-07-07 AU AU88063/98A patent/AU747199B2/en not_active Expired
- 1998-07-07 CN CNB988069571A patent/CN1195736C/zh not_active Expired - Lifetime
- 1998-07-07 ID IDW20000036D patent/ID24481A/id unknown
- 1998-07-07 EE EEP200000015A patent/EE04178B1/xx unknown
- 1998-07-07 TR TR2000/00023T patent/TR200000023T2/xx unknown
- 1998-07-07 HU HU0002539A patent/HU227424B1/hu unknown
- 1998-07-07 DK DK98940158T patent/DK0991410T3/da active
- 1998-07-07 DK DK98939620T patent/DK1000028T3/da active
- 1998-07-07 NZ NZ502208A patent/NZ502208A/en unknown
- 1998-07-07 CA CA002295087A patent/CA2295087C/en not_active Expired - Lifetime
- 1998-07-07 PT PT98939620T patent/PT1000028E/pt unknown
- 1998-07-07 PL PL98338005A patent/PL190310B1/pl not_active IP Right Cessation
- 1998-07-07 KR KR10-1999-7012492A patent/KR100500372B1/ko not_active IP Right Cessation
- 1998-07-07 EA EA200000110A patent/EA002619B1/ru not_active IP Right Cessation
- 1998-07-07 NZ NZ502209A patent/NZ502209A/xx not_active IP Right Cessation
- 1998-07-07 AT AT98940158T patent/ATE226820T1/de active
- 1998-07-07 DE DE69820065T patent/DE69820065T2/de not_active Expired - Lifetime
- 1998-07-07 AT AT98939620T patent/ATE255092T1/de not_active IP Right Cessation
- 1998-07-07 SI SI9830579T patent/SI1000028T1/xx unknown
- 1998-07-07 CZ CZ0463899A patent/CZ297298B6/cs not_active IP Right Cessation
- 1998-07-07 TR TR2000/00022T patent/TR200000022T2/xx unknown
- 1998-07-07 PL PL98338008A patent/PL190611B1/pl unknown
- 1998-07-07 CZ CZ19994587A patent/CZ295506B6/cs not_active IP Right Cessation
- 1998-07-07 EP EP98939620A patent/EP1000028B1/en not_active Expired - Lifetime
- 1998-07-07 AU AU88574/98A patent/AU734475B2/en not_active Expired
- 1998-07-07 BR BR9811687-8A patent/BR9811687A/pt active Search and Examination
- 1998-07-07 DE DE69809050T patent/DE69809050T2/de not_active Expired - Lifetime
- 1998-07-07 SI SI9830311T patent/SI0991410T1/xx unknown
- 1998-07-07 ES ES98940158T patent/ES2187051T3/es not_active Expired - Lifetime
- 1998-07-07 IL IL13391898A patent/IL133918A/en not_active IP Right Cessation
- 1998-07-07 JP JP50812599A patent/JP2002508000A/ja active Pending
- 1998-07-07 HU HU0004564A patent/HUP0004564A3/hu unknown
- 1998-07-07 US US09/462,287 patent/US6452013B1/en not_active Expired - Lifetime
- 1998-07-07 SK SK1840-99A patent/SK284942B6/sk not_active IP Right Cessation
- 1998-07-07 CA CA002295088A patent/CA2295088C/en not_active Expired - Lifetime
- 1998-07-07 BR BRPI9811688 patent/BRPI9811688B8/pt not_active IP Right Cessation
- 1998-07-07 ES ES98939620T patent/ES2212330T3/es not_active Expired - Lifetime
- 1998-07-08 MY MYPI98003106A patent/MY123199A/en unknown
- 1998-07-08 MY MYPI98003107A patent/MY117803A/en unknown
- 1998-07-10 AR ARP980103374A patent/AR013361A1/es active IP Right Grant
- 1998-07-10 AR ARP980103373A patent/AR016324A1/es active IP Right Grant
-
1999
- 1999-12-10 BG BG103984A patent/BG64230B1/bg unknown
- 1999-12-10 BG BG103983A patent/BG63709B1/bg unknown
-
2000
- 2000-01-05 HR HR20000005A patent/HRP20000005B1/xx not_active IP Right Cessation
- 2000-01-05 HR HR20000006A patent/HRP20000006B1/xx not_active IP Right Cessation
- 2000-01-10 NO NO20000115A patent/NO314662B1/no not_active IP Right Cessation
- 2000-01-10 NO NO20000116A patent/NO317467B1/no not_active IP Right Cessation
- 2000-07-08 HK HK00104201A patent/HK1025093A1/xx not_active IP Right Cessation
- 2000-07-08 HK HK00104203A patent/HK1025047A1/xx not_active IP Right Cessation
-
2001
- 2001-02-22 US US09/791,227 patent/US6635643B2/en not_active Ceased
-
2002
- 2002-06-05 US US10/162,802 patent/US6750349B2/en not_active Expired - Lifetime
-
2003
- 2003-08-19 US US10/643,506 patent/US20040058958A1/en not_active Abandoned
-
2005
- 2005-10-26 US US11/259,719 patent/USRE40793E1/en not_active Expired - Lifetime
-
2006
- 2006-02-16 US US11/355,326 patent/US20060142341A1/en not_active Abandoned
- 2006-02-17 US US11/357,884 patent/US20060142342A1/en not_active Abandoned
- 2006-10-20 US US11/584,732 patent/US7790750B2/en not_active Expired - Fee Related
-
2010
- 2010-05-04 US US12/773,183 patent/US8063070B2/en not_active Expired - Fee Related
-
2011
- 2011-09-20 US US13/237,330 patent/US8318742B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100500372B1 (ko) | 위장운동 조절성 3- 또는 4-치환된4-(아미노메틸)-피페리딘 유도체의 비사이클릭 벤즈아미드 | |
US6544997B1 (en) | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | |
KR100702526B1 (ko) | 피롤리디닐, 피페리디닐 또는 호모피페리디닐 치환된(벤조디옥산, 벤조푸란 또는 벤조피란) 유도체 | |
MXPA00000418A (en) | Gastrokinetic monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | |
MXPA00000417A (en) | Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130603 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20140603 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20150518 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20160527 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20170601 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20180529 Year of fee payment: 14 |
|
EXPY | Expiration of term |